DC-CIK as a widely applicable cancer immunotherapy. (2nd June 2020)

• Record Type: Journal Article
• Authors: Wang, Shuo; Wang, Xiaoli; Zhou, Xinna; Lyerly, Herbert Kim; Morse, Michael A.; Ren, Jun
• Is Part Of: Expert opinion on biological therapy. Volume 20:Number 6(2020)
• Page Start: 601
• Page End: 607
• Publication Date: 2020-06-02
• Subjects: DC-CIK -- immunotherapy -- solid Cancer -- clinical Trail; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2020.1728250
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction : Immunotherapy is now a standard treatment for many malignancies. Although immune checkpoint inhibition has demonstrated substantial efficacy by enhancing T cell activation and function in the tumor microenvironment, adoptive transfer of T and NK cell products promises to provide activated cells capable of immediate and direct tumor destruction. A widely applicable, non-MHC dependent, cellular therapy, consisting of in vitro generated dendritic cells (DC) combined with cytokine-induced killer cells (CIK), is highly efficient to produce from individual patients and has demonstrated safety and efficacy alone or with chemotherapy. Areas covered : We summarize the clinical data from studies of DC-CIK and discuss future research directions. Expert opinion : Patients with a wide variety of tumor types who have received DC-CIK therapy may experience clinical responses. This versatile therapy synergizes with other anti-cancer therapies including chemotherapy and immunotherapy.